12 research outputs found
Isolated IgG4-related interstitial lung disease: unusual histological and radiological features of a pathologically proven case
IgG4-related lung disease is commonly associated with autoimmune pancreatitis. Recently, isolated IgG4-related interstitial lung disease (ILD) without other organ involvement has newly been reported in two cases with clinical features of nonspecific interstitial pneumonitis (NSIP). We report the first case of an isolated IgG4-related ILD in a 78-year-old man with dry cough and dyspnea, whose clinical findings proved to be different from NSIP. Serum IgG4 levels were increased. Chest CT scan revealed bilateral consolidations especially in the lower lobes, enlarged mediastinal and hilar lymph nodes and pleural effusions. Video-assisted thoracoscopic (VATS) lung biopsy revealed a pattern similar to usual interstitial pneumonia (UIP) and an abundant IgG4-positive plasma cell infiltration. He was effectively treated by steroid therapy. Increasing recognition of IgG4 related diseases has led to a growing number of new entities. The novel concept of isolated IgG4-related ILD as a pulmonary manifestation of a systemic IgG4-related disorder should be taken into account as a possible differential diagnosis of ILD and mass-forming lesions, even when no other organ manifestation is clinically apparent at the time of diagnosis. Lung specific diagnostic criteria and algorithms are required to enhance diagnostic accuracy in cases of possible IgG4-related ILD
Midregional Proatrial Natriuretic Peptide (MRproANP) is associated with vertebral fractures and low bone density in patients with chronic obstructive pulmonary disease (COPD)
Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort
Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD—results from COSYCONET
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
Introduction: Pulmonary hypertension (PH) is a common complication in patients with
congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course
of the underlying anomaly. The various CHDs differ substantially in characteristics, functionality, and
clinical outcomes among each other and compared with other diseases with pulmonary hypertension.
Objective: To describe current management strategies and outcomes for adults with PH in relation to
different types of CHD based on real-world data. Methods and results: COMPERA (Comparative,
Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) is a prospective,
international PH registry comprising, at the time of data analysis, >8200 patients with various forms of
PH. Here, we analyzed a subgroup of 680 patients with PH due to CHD, who were included between
2007 and 2018 in 49 specialized centers for PH and/or CHD located in 11 European countries. At
enrollment, the patients’ median age was 44 years (67% female), and patients had either pre-tricuspid
shunts, post-tricuspid shunts, complex CHD, congenital left heart or aortic disease, or miscellaneous
other types of CHD. Upon inclusion, targeted therapies for pulmonary arterial hypertension (PAH) included endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and soluble
guanylate cyclase stimulators. Eighty patients with Eisenmenger syndrome were treatment-naïve.
While at inclusion the primary PAH treatment for the cohort was monotherapy (70% of patients),
with 30% of the patients on combination therapy, after a median observation time of 45.3 months,
the number of patients on combination therapy had increased significantly, to 50%. The use of oral
anticoagulants or antiplatelets was dependent on the underlying diagnosis or comorbidities. In the
entire COMPERA-CHD cohort, after follow-up and receiving targeted PAH therapy (n = 511), 91
patients died over the course of a 5-year follow up. The 5-year Kaplan–Meier survival estimate for
CHD associated PH was significantly better than that for idiopathic PAH (76% vs. 54%; p < 0.001).
Within the CHD associated PH group, survival estimates differed particularly depending on the
underlying diagnosis and treatment status. Conclusions: In COMPERA-CHD, the overall survival of
patients with CHD associated PH was dependent on the underlying diagnosis and treatment status,
but was significantly better as than that for idiopathic PAH. Nevertheless, overall survival of patients
with PAH due to CHD was still markedly reduced compared with survival of patients with other
types of CHD, despite an increasing number of patients on PAH-targeted combination therapy
Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy.
The importance of clinical predictors in the treatment of non-small-cell lung cancer (NSCLC) has increased during the last decade. This retrospective study analyzed the combined patient-level data from two phase II trials that investigated the efficacy and safety of combination chemotherapy with vinorelbine and mitomycin in patients with locally advanced or metastatic NSCLC. The aim of this analysis was to determine if patients' baseline and disease characteristics, including histology, gender, smoking history, and expression of TTF-1, might be potential predictors of outcome.Journal ArticleSCOPUS: ar.jinfo:eu-repo/semantics/publishe
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients.PATIENTS AND METHODS:1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. RESULTS: 19 patients of 1035 evaluable (1.8%) had OS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations. CONCLUSION: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCL
Impact of continuous, non-invasive blood pressure measurement on sleep quality during polysomnography
ROS1 rearrangements in lung adenocarcinoma : prognostic impact, therapeutic options and genetic variability
Background: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1- positive patients.
Patients and methods: 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients.
Results: 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations.
Conclusion: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC
Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1-4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV1, FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin. Among 2741 patients, 1541 (mean age 64.4 y, 601 female) fulfilled the inclusion criteria. In the group with metformin treatment vs. non-diabetes the mean annual decline in KCO and TLCO was significantly lower (0.2 vs 2.3, 0.8 vs. 2.8%predicted, respectively;p < 0.05 each), but not the decline of FEV1 and FVC. These results were confirmed using multiple regression and propensity score analyses. Our findings demonstrate an association between the annual decline of lung diffusing capacity and the intake of metformin in patients with COPD consistent with the hypothesis of anti-aging effects of metformin as reflected in a surrogate marker of emphysema